Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
You may also be interested in...
Based on the current pipeline of durable therapies, MIT research indicates ‘it’s not a big lift to cover the children and the adults in Medicaid for these products,’ Mark Trusheim says.
Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden.
Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.